Published in Blood on September 28, 2009
Functional characterization of newly-discovered mutations in human SR-BI. PLoS One (2012) 0.87
The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood (2010) 0.87
Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem (2011) 0.84
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol (2010) 2.48
Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med (2007) 2.37
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol (2002) 1.78
Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). Blood (2010) 1.75
Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice--brief report. Arterioscler Thromb Vasc Biol (2010) 1.74
Matrix-specific suppression of integrin activation in shear stress signaling. Mol Biol Cell (2006) 1.67
Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood (2009) 1.65
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood (2008) 1.45
Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba. Thromb Haemost (2006) 1.43
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica (2008) 1.41
Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog (2007) 1.41
SCAMP5, NBEA and AMISYN: three candidate genes for autism involved in secretion of large dense-core vesicles. Hum Mol Genet (2010) 1.38
Platelets at work in primary hemostasis. Blood Rev (2011) 1.34
Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem (2005) 1.34
Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem (2011) 1.33
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS (2004) 1.28
Identification of the LEDGF/p75 binding site in HIV-1 integrase. J Mol Biol (2006) 1.24
Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood (2004) 1.22
LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One (2011) 1.19
Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood (2003) 1.18
Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood (2010) 1.16
Unwinding the von Willebrand factor strings puzzle. Blood (2012) 1.13
von Willebrand factor to the rescue. Blood (2009) 1.13
Functional polymorphisms in the paternally expressed XLalphas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation. Hum Mol Genet (2003) 1.12
Binding of the concave surface of the Sds22 superhelix to the alpha 4/alpha 5/alpha 6-triangle of protein phosphatase-1. J Biol Chem (2002) 1.11
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother (2008) 1.10
Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One (2012) 1.09
The TUBB1 Q43P functional polymorphism reduces the risk of cardiovascular disease in men by modulating platelet function and structure. Blood (2005) 1.08
Platelet adhesion to collagen. Thromb Res (2011) 1.04
Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet (2002) 1.03
Evidence for DNA-binding domain--ligand-binding domain communications in the androgen receptor. Mol Cell Biol (2012) 1.03
Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb Haemost (2002) 1.03
Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol (2008) 1.02
Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol (2009) 1.01
Role of glycoprotein Ibalpha in phagocytosis of platelets by macrophages. Transfusion (2006) 1.01
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol (2007) 1.01
Identification of residues within human glycoprotein VI involved in the binding to collagen: evidence for the existence of distinct binding sites. J Biol Chem (2004) 1.00
Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood (2010) 1.00
The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J Clin Invest (2004) 0.99
Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood (2006) 0.99
Structural basis for the high Ca2+ affinity of the ubiquitous SERCA2b Ca2+ pump. Proc Natl Acad Sci U S A (2009) 0.99
Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol (2005) 0.99
Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost (2006) 0.98
Accuracy of PfHRP2 versus Pf-pLDH antigen detection by malaria rapid diagnostic tests in hospitalized children in a seasonal hyperendemic malaria transmission area in Burkina Faso. Malar J (2014) 0.98
Antiplatelet drugs. Br J Haematol (2008) 0.98
Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol (2004) 0.97
Inherited traits affecting platelet function. Blood Rev (2008) 0.97
-391 C to G substitution in the regulator of G-protein signalling-2 promoter increases susceptibility to the metabolic syndrome in white European men: consistency between molecular and epidemiological studies. J Hypertens (2007) 0.96
Model systems of genetically modified platelets. Blood (2011) 0.96
Activation of alphaIIbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets. Blood (2006) 0.95
Tuning the size and properties of ClyA nanopores assisted by directed evolution. J Am Chem Soc (2013) 0.95
The dead-end elimination method, tryptophan rotamers, and fluorescence lifetimes. Biophys J (2003) 0.93
Rhabdomyolysis in diabetic ketoacidosis. Pediatr Diabetes (2003) 0.91
Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost (2013) 0.91
Monoclonal antibody IAC-1 is specific for activated alpha2beta1 and binds to amino acids 199 to 201 of the integrin alpha2 I-domain. Blood (2004) 0.91
Molecular cloning and characterization of the GATA1 cofactor human FOG1 and assessment of its binding to GATA1 proteins carrying D218 substitutions. Hum Genet (2002) 0.90
GNAS defects identified by stimulatory G protein alpha-subunit signalling studies in platelets. J Clin Endocrinol Metab (2008) 0.90
PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications. Blood (2007) 0.90
Pseudohypoparathyroidism type Ib with disturbed imprinting in the GNAS1 cluster and Gsalpha deficiency in platelets. Hum Mol Genet (2002) 0.89
Blood platelet biochemistry. Thromb Res (2011) 0.89
Two functional active conformations of the integrin {alpha}2{beta}1, depending on activation condition and cell type. J Biol Chem (2005) 0.89
The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost (2008) 0.89
Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. J Acquir Immune Defic Syndr (2008) 0.89
Von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord Drug Targets (2009) 0.89
Methylation defect in imprinted genes detected in patients with an Albright's hereditary osteodystrophy like phenotype and platelet Gs hypofunction. PLoS One (2012) 0.89
A new approach to imprinting mutation detection in GNAS by Sequenom EpiTYPER system. Clin Chim Acta (2010) 0.88